Samsali Wart Corn Remover Pads

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided in the available data.

Uses and Indications

This drug is indicated for the removal of warts and corns.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly. Soaking the wart in warm water for 5 minutes is optional but may enhance the effectiveness of the treatment. After washing, the area must be dried completely. If necessary, the medicated plaster can be cut to fit the size of the wart.

The medicated plaster should then be applied directly to the wart. This procedure may be repeated every 48 hours as needed, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

The product is contraindicated for use on irritated, infected, or reddened skin, as well as on genital warts, facial warts, moles, birthmarks, or warts with hair growing from them. Application to mucous membranes is also prohibited.

Contact with the eyes or face should be avoided; in the event of exposure, the affected area must be thoroughly rinsed with water.

Warnings and Precautions

For external use only. This product is not intended for ingestion. In the event of accidental swallowing, it is imperative to seek medical assistance immediately or contact a Poison Control Center for guidance.

Healthcare professionals should advise patients to discontinue use and consult their physician if discomfort persists. Monitoring for any adverse reactions is essential to ensure patient safety and effective management of any potential side effects.

Side Effects

Patients should be aware that the product is intended for external use only. In the event that discomfort persists after application, it is advised to discontinue use and consult a healthcare professional.

Additionally, individuals with diabetes or poor blood circulation are encouraged to seek medical advice prior to using this product to ensure safety and appropriateness for their specific health conditions.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified in the available data. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Samsali Wart Corn Remover Pads (wart corn remover pads). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep the medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

The safety of this product during pregnancy has not been established, as the prescribing information does not provide specific data regarding its use in pregnant patients. There are no known safety concerns, dosage modifications, or special precautions outlined for women who are pregnant or may become pregnant. Healthcare professionals should weigh the potential benefits against any unknown risks when considering this product for use in pregnant patients. It is advisable to monitor for any adverse effects and to counsel patients on the lack of available data regarding the use of this product during pregnancy.

Lactation

There is no information available regarding the use of SAMSALI WART CORN REMOVER PADS in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider this lack of data when advising lactating patients.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide the management of the overdose effectively. Additionally, healthcare professionals should refer to local protocols and guidelines for the management of overdose situations, as these may provide specific recommendations based on the substance involved.

Overall, vigilance and prompt intervention are critical in managing any suspected overdose scenario.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients that the product should not be applied to irritated, infected, or reddened skin, as well as on genital warts, warts on the face, moles, birthmarks, or warts with hair growing from them, and on mucous membranes.

Patients should be counseled to report any persistent discomfort following the use of the product. Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes or face. In the event that the product comes into contact with these areas, patients should be instructed to thoroughly rinse with water.

Providers should also discuss the implications of underlying health conditions, such as diabetes and poor blood circulation, as these may affect the use of the product and the patient's overall treatment plan.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within a temperature range of 59° to 86°F (15°C to 30°C) to maintain its efficacy and integrity. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable environment to prevent degradation.

Additional Clinical Information

The medication is administered topically, with the application of a medicated plaster. Patients are instructed to repeat the procedure every 48 hours as needed until the wart is removed, with a maximum treatment duration of up to 12 weeks.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Samsali Wart Corn Remover Pads, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)